Varicella Virus Vaccine Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Evaluation of Immunogenicity and Safety of VARIVAX ™ Passage Extension 34 (PE34) Process in Children (V210-A03)
Condition: Varicella Interventions: Biological: VARIVAX™ PE34 Process; Biological: VARIVAX™ 2016 Commercial Process; Biological: M-M-R II™ Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting - verified July 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2017 Category: Research Source Type: clinical trials
